Joan Tosca

Blasco Ibañez Av. 17
Valencia, VC 46010, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

The TECCU-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter GETECCU Trial.

The TECCU-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter GETECCU Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 13, 2025

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma.

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 17, 2025

Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU.

Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU.

Journal: Journal of medical Internet research

Published: June 03, 2024

Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor.

Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor.

Journal: Cancer diagnosis & prognosis

Published: May 04, 2024

Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients.

Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients.

Journal: International journal of molecular sciences

Published: September 04, 2023

Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease.

Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 18, 2023

Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors.

Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors.

Journal: Gastroenterologia y hepatologia

Published: August 04, 2022

Caustic Ingestion: A Risk-Based Algorithm.

Caustic Ingestion: A Risk-Based Algorithm.

Journal: The American journal of gastroenterology

Published: January 03, 2022

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy.

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy.

Journal: Scientific reports

Published: September 02, 2021

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

Journal: Cells

Published: May 17, 2021

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease.

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease.

Journal: Journal of clinical medicine

Published: May 11, 2021

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.

Journal: Gastroenterologia y hepatologia

Published: March 18, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026